Research progress on the treatment of acute kidney injury with nanomedicine

doi:10.3877/cma.j.issn.2095-3216.2025.05.007

Abstract

Abstract:

Acute kidney injury (AKI) is a common clinical complication closely related to chronic kidney disease. The unique physicochemical properties of nanomedicines provide advantages such as prolonging circulation time, enhancing delivery efficiency, bypassing the glomerular filtration barrier, and increasing renal accumulation of drugs, presenting new opportunities for the treatment of AKI. This article provided an overview of the pathophysiological processes of AKI, the preparation of biomimetic nanomedicines, the enhancement of drug targeting through surface modification of nanocarriers, the development of nanocarrier delivery systems responsive to AKI microenvironment stimuli, the prolongation of nanomedicine retention time in the kidney, and the enhancement of synergistic therapeutic effects of nanomedicines, offering a basis and new ideas for the development of effective nanomedicines for the treatment of AKI.

Key words: Acute kidney injury, Nanomedicine, Targeting, Therapy, Strategy

Yingjie Zhang, Yanhong Liu, Yueyun Fan, Zhengyang Quan, Jiaona Liu, Wanjun Shen, Qiang Lü, Mengjie Huang, Jinfeng Zhang. Research progress on the treatment of acute kidney injury with nanomedicine[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2025, 14(05): 288-293.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2025.05.007

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2025/V14/I05/288

Figures/Tables 1

References 58

[1]	Ba X, Ye T, Shang H, et al. Recent advances in nanomaterials for the treatment of acute kidney injury [J]. ACS Appl Mater Interfaces, 2024, 16(10): 12117-12148.
[2]	Hoste EA, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study [J]. Intensive Care Med, 2015, 41(8): 1411-1423.
[3]	Sato Y, Takahashi M, Yanagita M. Pathophysiology of AKI to CKD progression [J]. Semin Nephrol, 2020, 40(2), 206-215.
[4]	Qin W, Huang J, Zhang M, et al. Nanotechnology-based drug delivery systems for treating acute kidney injury [J]. ACS Biomater Sci Eng, 2024, 10(10): 6078-6096.
[5]	Roointan A, Xu R, Corrie S, et al. Nanotherapeutics in kidney disease: innovations, challenges, and future directions [J]. J Am Soc Nephrol, 2025, 36(3): 500-518.
[6]	Gholizadeh Z, Aliannezhadi M, Ghominejad M, et al. High specific surface area γ-Al2O3 nanoparticles synthesized by facile and low-cost co-precipitation method [J]. Sci Rep, 2023, 13(1): 6131.
[7]	Tomsa AM, Alexa AL, Junie ML, et al. Oxidative stress as a potential target in acute kidney injury [J]. PeerJ, 2019, 7: e8046.
[8]	Ostermann M, Liu K. Pathophysiology of AKI [J]. Best Pract Res Clin Anaesthesiol, 2017, 31(3): 305-314.
[9]	McCullough PA, Choi JP, Feghali GA, et al. Contrast-induced acute kidney injury [J]. J Am Coll Cardiol, 2016, 68(13): 1465-1473.
[10]	Quan Z, Wang S, Xie H, et al. ROS regulation in CNS disorder therapy: unveiling the dual roles of nanomedicine [J]. Small, 2025, 21(5): e2410031.
[11]	Ostermann M, Lumlertgul N, Jeong R, et al. Acute kidney injury [J]. Lancet, 2025, 405(10474): 241-256.
[12]	Li L, Shen Y, Tang Z, et al. Engineered nanodrug targeting oxidative stress for treatment of acute kidney injury [J]. Exploration (Beijing), 2023, 3(6): 20220148.
[13]	Ahmad A, Dempsey SK, Daneva Z, et al. Role of nitric oxide in the cardiovascular and renal systems [J]. Int J Mol Sci, 2018, 19(9): 2605.
[14]	Zhang X, Liang L, Wang F, et al. Irisin-encapsulated mitochondria-targeted biomimetic nanotherapeutics for alleviating acute kidney injury [J]. Adv Sci (Weinh), 2024, 11(38): e2402805.
[15]	Xiong J, Zhao J. Pyroptosis: the determinator of cell death and fate in acute kidney injury [J]. Kidney Dis (Basel), 2023, 10(2): 118-131.
[16]	Li N, Wang Y, Wang X, et al. Pathway network of pyroptosis and its potential inhibitors in acute kidney injury [J]. Pharmacol Res, 2022, 175: 106033.
[17]	Chen Z, Chen P, Zhu Y, et al. Cobalt oxyhydroxide nanozymes inhibit inflammation by targeting the NLRP3 inflammasome [J]. Adv Funct Mater, 2023, 33: 2370163.
[18]	Qin S, Liu C, Chen Y, et al. Cobaltosic oxide-polyethylene glycol-triphenylphosphine nanoparticles ameliorate the acute-to-chronic kidney disease transition by inducing BNIP3-mediated mitophagy [J]. Kidney Int, 2023, 103(5): 903-916.
[19]	Bai X, Kang J, Wei S, et al. A pH responsive nanocomposite for combination sonodynamic-immunotherapy with ferroptosis and calcium ion overload via SLC7A11/ACSL4/LPCAT3 pathway [J]. Exploration (Beijing), 2025, 5(1): 20240002.
[20]	Yu Y, Zhang L, Zhang D, et al. The role of ferroptosis in acute kidney injury: mechanisms and potential therapeutic targets [J]. Mol Cell Biochem, 2025, 480(2): 759-784.
[21]	Cao Y, Liu X, Guo C, et al. Biomimetic reactive oxygen/nitrogen nanoscavengers inhibit "ferroptosis storm" and modulate immune targeting for acute kidney injury [J]. J Control Release, 2025, 379: 59-76.
[22]	Li Y, Wang G, Wang T, et al. PEGylated gambogic acid nanoparticles enable efficient renal-targeted treatment of acute kidney injury [J]. Nano Lett, 2023, 23(12): 5641-5647.
[23]	Xu M, Qi Y, Liu G, et al. Size-dependent in vivo transport of nanoparticles: implications for delivery, targeting, and clearance [J]. ACS Nano, 2023, 17(21): 20825-20849.
[24]	Song J, Yu J, Prayogo GW, et al. Understanding kidney injury molecule 1: a novel immune factor in kidney pathophysiology [J]. Am J Transl Res, 2019, 11(3): 1219-1229.
[25]	Wajda J, Dumnicka P, Kolber W, et al. The marker of tubular injury, kidney injury molecule-1 (KIM-1), in acute kidney injury complicating acute pancreatitis: a preliminary study [J]. J Clin Med, 2020, 9(5): 1463.
[26]	Yu H. HDL and scavenger receptor class B type I (SRBI) [J]. Adv Exp Med Biol, 2022, 1377: 79-93.
[27]	He S, Li X, He Y, et al. High-density lipoprotein nanoparticles spontaneously target to damaged renal tubules and alleviate renal fibrosis by remodeling the fibrotic niches [J]. Nat Commun, 2025, 16(1): 1061.
[28]	Huang Z, Chun C, Li X. Kidney targeting peptide-modified biomimetic nanoplatforms for treatment of acute kidney injury [J]. J Control Release, 2023, 358: 368-381.
[29]	Sun M, Yang J, Fan Y, et al. Beyond extracellular vesicles: hybrid membrane nanovesicles as emerging advanced tools for biomedical applications [J]. Adv Sci (Weinh), 2023, 10(32): e2303617.
[30]	Li M, Fang F, Sun M, et al. Extracellular vesicles as bioactive nanotherapeutics: an emerging paradigm for regenerative medicine [J]. Theranostics, 2022, 12(11): 4879-4903.
[31]	Sun M, Li M, Hu M, et al. Fully bioactive nanodrugs: stem cell-derived exosomes engineered with biomacromolecules to treat CCl4- and extreme hepatectomy-induced acute liver failure [J]. ACS Nano, 2024, 18(50): 33907-33921.
[32]	Tang TT, Lv LL, Wang B, et al. Employing macrophage-derived microvesicle for kidney-targeted delivery of dexamethasone: an efficient therapeutic strategy against renal inflammation and fibrosis [J]. Theranostics, 2019, 9(16): 4740-4755.
[33]	Chen Q, Ding F, Zhang S, et al. Sequential therapy of acute kidney injury with a DNA nanodevice [J]. Nano Lett, 2021, 21(10): 4394-4402.
[34]	覃宛冰，刘庆华. 利用靶向纳米药物治疗急性肾损伤研究进展[J/OL]. 中华肾病研究电子杂志，2025, 14(3): 121-125.
[35]	Wang L, Zhou W, Chen H, et al. Barcoded screening identifies nanocarriers for protein delivery to kidney [J]. Nat Commun, 2025, 16(1): 899.
[36]	Gu XR, Tai YF, Liu Z, et al. Layer-by-layer assembly of renal-targeted polymeric nanoparticles for robust arginase-2 knockdown and contrast-induced acute kidney injury prevention [J]. Adv Healthc Mater, 2024, 13(20): e2304675.
[37]	Huang ZW, Shi Y, Zhai YY, et al. Hyaluronic acid coated bilirubin nanoparticles attenuate ischemia reperfusion-induced acute kidney injury [J]. J Control Release, 2021, 334: 275-289.
[38]	Liu D, Jin F, Shu G, et al. Enhanced efficiency of mitochondria-targeted peptide SS-31 for acute kidney injury by pH-responsive and AKI-kidney targeted nanopolyplexes [J]. Biomaterials, 2019, 211: 57-67.
[39]	Yu H, Jin F, Liu D, et al. ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury [J]. Theranostics, 2020, 10(5): 2342-2357.
[40]	Yang L, Dong S, Gai S, et al. Deep insight of design, mechanism, and cancer theranostic strategy of nanozymes [J]. Nanomicro Lett, 2023, 16(1): 28.
[41]	Lu Y, Cao C, Pan X, et al. Structure design mechanisms and inflammatory disease applications of nanozymes [J]. Nanoscale, 2022, 15(1): 14-40.
[42]	Singh S. Antioxidant nanozymes as next-generation therapeutics to free radical-mediated inflammatory diseases: a comprehensive review [J]. Int J Biol Macromol, 2024, 260(Pt 1): 129374.
[43]	Zhang F, Gao P, Qi M, et al. An artificial peroxynitrite-resistant superoxide dismutase for acute kidney injury alleviation [J]. Small, 2025, 26: e2503033.
[44]	Rezaei B, Yari P, Sanders SM, et al. Magnetic nanoparticles: a review on synthesis, characterization, functionalization, and biomedical applications [J]. Small, 2024, 20(5): e2304848.
[45]	Wu K, Su D, Liu J, et al. Magnetic nanoparticles in nanomedicine: a review of recent advances [J]. Nanotechnology, 2019, 30(50): 502003.
[46]	Wang J, Zha M, Zhao H, et al. Detection of kidney dysfunction through in vivo magnetic resonance imaging with renal-clearable gadolinium nanoprobes [J]. Anal Chem, 2022, 94(9): 4005-4011.
[47]	Zhou T, Dong Y, Wang X, et al. Highly sensitive early diagnosis of kidney damage using renal clearable zwitterion-coated ferrite nanoprobe via magnetic resonance imaging in vivo [J]. Adv Healthc Mater, 2024, 13(12): e2304577.
[48]	Sharma I, Sharaf MG, Pawar A, et al. Hemocompatibility of albumin-modified magnetic nanoparticles [J]. Int J Mol Sci, 2024, 25(22): 11975.
[49]	Liu L, Xu Q, Zhang L, et al. Fe₃O₄ magnetic nanoparticles ameliorate albumin-induced tubulointerstitial fibrosis by autophagy related to Rab7 [J]. Colloids Surf B Biointerfaces, 2021, 198: 111470.
[50]	Li J, Duan Q, Wei X, et al. Kidney-targeted nanoparticles loaded with the natural antioxidant rosmarinic acid for acute kidney injury treatment [J]. Small, 2022, 18(48): e2204388.
[51]	Lei Y, Wu Y, Zhuang WR, et al. NAD^＋ biosynthesis and mitochondrial repair in acute kidney injury via ultrasound-responsive thylakoid-integrating liposomes [J]. Nat Biomed Eng, 2025, 9(10): 1740-1757.
[52]	Ding L, Liang X, Ma J, et al. Sono-triggered biomimetically nanoantibiotics mediate precise sequential therapy of MRSA-induced lung infection [J]. Adv Mater, 2024, 36(46): e2403612.
[53]	Xu Y, Zhang Q, Chen R, et al. NIR-II photoacoustic-active DNA origami nanoantenna for early diagnosis and smart therapy of acute kidney injury [J]. J Am Chem Soc, 2022, 144(51): 23522-23533.
[54]	Zeng F, Nijiati S, Liu Y, et al. Ferroptosis MRI for early detection of anticancer drug-induced acute cardiac/kidney injuries [J]. Sci Adv, 2023, 9(10): eadd8539.
[55]	Sun J, Han Y, Dong J, et al. Melanin/melanin-like nanoparticles: as a naturally active platform for imaging-guided disease therapy [J]. Mater Today Bio, 2023, 23: 100894.
[56]	Zhao X, Sun J, Dong J, et al. An auto-photoacoustic melanin-based drug delivery nano-platform for self-monitoring of acute kidney injury therapy via a triple-collaborative strategy [J]. Acta Biomater, 2022, 147: 327-341.
[57]	Fang F, Wang S, Song Y, et al. Continuous spatiotemporal therapy of a full-API nanodrug via multi-step tandem endogenous biosynthesis [J]. Nat Commun, 2023, 14(1): 1660.
[58]	Zhang C, Zhao D, Fang F, et al. Quintuple free-radical therapy: an ultralong-retention FAND for NIR-involved multiple site-action hypoxic tumor therapy [J]. Adv Funct Mater, 2024, 34(37): 2401840.

Please choose a citation manager

Content to export